Want to see CVSI full AI Analyst Report?
Top Page
CV Sciences
(OTC:CVSI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.02
▲(20.00% Upside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and negative TTM free cash flow) and bearish technical signals (below long-term averages with negative MACD). Offsetting this modestly is a more constructive earnings-call outlook pointing to improving operating discipline and a targeted path to positive operating cash flow in H2 2026, but low cash levels and continued top-line pressure keep overall risk elevated.
Positive Factors
Leading hemp-extract brand
Being the #1 hemp-extract brand in natural product retail is a durable competitive advantage: strong shelf placement, retailer relationships, and brand recognition support recurring wholesale and DTC demand, making share retention and margin recovery easier as the category consolidates.
Negative Factors
Persistent top-line decline
Multi-year and recent revenue declines highlight structural demand weakness in the core CBD category. Sustained top-line erosion reduces scale, weakens gross profit conversion, and makes it harder to cover fixed costs, raising execution risk for a return to profitable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Leading hemp-extract brand
Being the #1 hemp-extract brand in natural product retail is a durable competitive advantage: strong shelf placement, retailer relationships, and brand recognition support recurring wholesale and DTC demand, making share retention and margin recovery easier as the category consolidates.
Read all positive factors
CV Sciences (CVSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.65M
Dividend YieldN/A
Average Volume (3M)246.65K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth-14.90%
EPS Growth-22.35%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding225,829,130
10 Day Avg. Volume158,629
30 Day Avg. Volume246,649
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CV Sciences Business Overview & Revenue Model
Company Description
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division...
How the Company Makes Money
CV Sciences makes money primarily by selling hemp-derived CBD consumer products. Its core revenue stream is product sales (e.g., ingestible CBD formulations like gummies, capsules, tinctures, and related wellness items, as well as topical products...
CV Sciences Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.76M | 13.79M | 15.71M | 16.00M | 16.20M | 20.05M |
| Gross Profit | 6.26M | 6.75M | 7.17M | 7.08M | 5.55M | 8.62M |
| EBITDA | -1.18M | -562.00K | -1.86M | 3.85M | -5.66M | -14.00M |
| Net Income | -2.01M | -958.00K | -2.39M | 3.10M | -8.21M | -15.55M |
Balance Sheet | ||||||
| Total Assets | 6.52M | 6.96M | 7.93M | 26.35M | 12.74M | 18.07M |
| Cash, Cash Equivalents and Short-Term Investments | 266.00K | 278.00K | 454.00K | 1.32M | 611.00K | 1.38M |
| Total Debt | 1.25M | 1.61M | 779.00K | 442.00K | 1.53M | 922.00K |
| Total Liabilities | 4.95M | 5.49M | 6.13M | 23.44M | 13.51M | 14.52M |
| Stockholders Equity | 1.57M | 1.47M | 1.79M | 2.90M | -777.00K | 3.54M |
Cash Flow | ||||||
| Free Cash Flow | -522.00K | -516.00K | -879.00K | 2.25M | -1.89M | -7.52M |
| Operating Cash Flow | -492.00K | -407.00K | -861.00K | 2.25M | -1.89M | -7.49M |
| Investing Cash Flow | -30.00K | -109.00K | -28.00K | -156.00K | 0.00 | -35.00K |
| Financing Cash Flow | -98.00K | 337.00K | 32.00K | -1.39M | 1.12M | 4.37M |
CV Sciences Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.03
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
8.95
Positive
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 8.95 is Positive, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVSI.
CV Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $5.55M | -1.62 | -33.59% | ― | 10.01% | 95.01% | |
45 Neutral | $39.24M | -1.46 | -92.47% | ― | -100.00% | 54.21% | |
44 Neutral | $5.65M | -2.88 | -94.61% | ― | -14.90% | -22.35% | |
44 Neutral | $13.53M | -0.33 | -96.48% | ― | 29.75% | 37.35% | |
41 Neutral | $1.10M | -1,062.50 | -3.03% | ― | -11.91% | -285.23% |
* Healthcare Sector Average
CVSI
CV Sciences
0.03
-0.01
-35.90%
YCBD
cbdMD
0.50
-0.19
-27.21%
COSM
Cosmos Holdings
0.22
-0.63
-74.41%
IMCC
IM Cannabis Corp
0.12
-2.46
-95.27%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.28
-8.72
-72.66%
CV Sciences Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
CV Sciences Reports Q2 Results Amid Regulatory Reprieve
Negative
Aug 13, 2026
On August 13, 2026, CV Sciences reported second-quarter 2026 results showing revenue of $3.0 million, down 17.5% from a year earlier, as restrictive federal and state regulations weighed on sales volumes and reduced units sold by 14.9%. Despite th...
Executive/Board ChangesShareholder MeetingsStock Split
CV Sciences Shareholders Elect Directors, Reject Reverse Stock Split
Neutral
Jun 4, 2026
On June 2, 2026, CV Sciences, Inc. held its 2026 Annual Meeting of Stockholders in virtual format, with approximately 60.1% of the 193,458,420 outstanding common shares represented by proxy, establishing a quorum for corporate governance decisions...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.